

HNL/CS/ 926  
October 26, 2016

# HIGHNOON LABORATORIES LTD.



**The General Manager,**  
Pakistan Stock Exchange Limited,  
Stock Exchange Building,  
Stock Exchange Road,  
**KARACHI.**

**Registered, Head Office & Plant:**

17.5 Kilometer, Multan Road, Lahore - 53700 (Pakistan)  
P.O. Box 3318, Gulberg, Lahore-54660 (Pakistan)  
UAN : 111-000-465  
Fax : 92 - 42 - 37510037  
Email : info@highnoon.com.pk  
Web : www.highnoon-labs.com

Subject: **FINANCIAL RESULTS FOR THE 3<sup>rd</sup> QUARTER ENDED SEPTEMBER 30, 2016**

Dear Sir,

We have to inform you that the Board of Directors of our Company in the meeting held on October 26, 2016 at 11.00 a.m., at registered office 17.5 K.M. Multan Road, Lahore approved the accounts for the 3<sup>rd</sup> quarter ended September 30, 2016.

**Financial Results of the Company and Consolidated Financial Results with its subsidiary are attached herewith as Annexure I and Annexure II respectively.**


We will be sending you 200 copies of printed accounts for distribution amongst the members of the Exchange.

Thanking you and assurances of our highest considerations.

Yours faithfully,

**KHADIM HUSSAIN MIRZA,**  
Company Secretary

- **The Securities & Exchange Commission of Pakistan, Islamabad**
- **The Securities & Exchange Commission of Pakistan,**  
Companies Registration Office, Lahore





Annexure -I

**HIGHNOON LABORATORIES LIMITED**  
**CONDENSED INTERIM PROFIT AND LOSS ACCOUNT (UN-AUDITED)**  
**FOR THE NINE MONTH PERIOD ENDED 30 SEPTEMBER 2016**

	Nine Month Period Ended		Three Month Period Ended	
	30 September 2016	30 September 2015	30 September 2016	30 September 2015
	----- (Rupees) -----			
Sales - net	3,739,305,548	3,208,090,279	1,204,578,121	1,041,626,196
Cost of sales	<u>(1,960,197,683)</u>	<u>(1,686,600,963)</u>	<u>(643,465,357)</u>	<u>(537,122,739)</u>
<b>Gross profit</b>	<b>1,779,107,865</b>	<b>1,521,489,316</b>	<b>561,112,764</b>	<b>504,503,457</b>
Distribution, selling and promotional expenses	<b>(965,547,411)</b>	(845,645,573)	<b>(301,801,423)</b>	(276,232,266)
Administrative and general expenses	<b>(175,719,249)</b>	(186,541,154)	<b>(61,180,356)</b>	(61,357,525)
Research and development expenses	<b>(2,715,041)</b>	(2,349,576)	<b>(1,088,987)</b>	(784,307)
Other operating expenses	<b>(54,544,225)</b>	(42,606,393)	<b>(16,205,439)</b>	(11,416,210)
	<b>(1,198,525,926)</b>	<b>(1,077,142,696)</b>	<b>(380,276,205)</b>	<b>(349,790,308)</b>
	<b>580,581,939</b>	444,346,620	<b>180,836,559</b>	154,713,149
Other income	<b>10,305,579</b>	25,279,621	<b>1,898,897</b>	2,005,253
<b>Operating profit</b>	<b>590,887,518</b>	469,626,241	<b>182,735,456</b>	156,718,402
Finance cost	<b>(4,160,600)</b>	(8,103,864)	<b>(889,594)</b>	(2,661,976)
<b>Profit before taxation</b>	<b>586,726,918</b>	461,522,377	<b>181,845,862</b>	154,056,426
Taxation	<b>(187,102,262)</b>	(162,777,776)	<b>(53,127,267)</b>	(51,221,466)
<b>Profit after taxation</b>	<b>399,624,656</b>	298,744,601	<b>128,718,595</b>	102,834,960
		Restated		Restated
Earnings per share - basic and diluted	17.52	13.10	5.64	4.51



ANNEXURE "II"

**HIGHNOON LABORATORIES LIMITED**  
**CONDENSED INTERIM CONSOLIDATED PROFIT AND LOSS ACCOUNT (UN-AUDITED)**  
**FOR THE NINE MONTH PERIOD ENDED 30 SEPTEMBER 2016**

	Nine Month Period Ended		Three Month Period Ended	
	30 September 2016	30 September 2015	30 September 2016	30 September 2015
	----- (Rupees) -----			
Sales - net	3,739,305,548	3,208,090,279	1,204,578,121	1,041,626,196
Cost of sales	(1,960,197,683)	(1,686,600,963)	(643,465,357)	(537,122,739)
<b>Gross profit</b>	<b>1,779,107,865</b>	<b>1,521,489,316</b>	<b>561,112,764</b>	<b>504,503,457</b>
Distribution, selling and promotional expenses	(965,547,411)	(845,645,573)	(301,801,423)	(276,232,266)
Administrative and general expenses	(183,338,749)	(186,745,711)	(68,799,856)	(61,562,082)
Research and development expenses	(2,715,041)	(2,349,576)	(1,088,987)	(784,307)
Other operating expenses	(54,544,225)	(42,606,393)	(16,205,439)	(11,416,210)
	(1,206,145,426)	(1,077,347,253)	(387,895,705)	(349,994,865)
	572,962,439	444,142,063	173,217,059	154,508,592
Other income	10,305,579	25,279,621	1,898,897	2,005,253
<b>Operating profit</b>	<b>583,268,018</b>	<b>469,421,684</b>	<b>175,115,956</b>	<b>156,513,845</b>
Finance cost	(4,167,633)	(8,103,864)	(896,627)	(2,661,976)
<b>Profit before taxation</b>	<b>579,100,385</b>	<b>461,317,820</b>	<b>174,219,329</b>	<b>153,851,869</b>
Taxation	(187,102,262)	(162,777,776)	(53,127,267)	(51,221,466)
<b>Profit after taxation</b>	<b>391,998,123</b>	<b>298,540,044</b>	<b>121,092,062</b>	<b>102,630,403</b>
<b>Profit /(Loss) after tax attributable to:</b>				
Shareholders of the Parent	392,365,154	298,582,114	121,092,062	102,672,473
Non-controlling interest	(367,031)	(40,914)	-	(40,914)
	<b>391,998,123</b>	<b>298,540,044</b>	<b>121,092,062</b>	<b>102,630,403</b>
		Restated		Restated
<b>Earnings per share - basic and diluted</b>	<b>17.19</b>	<b>13.09</b>	<b>5.31</b>	<b>4.50</b>